ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy of cognitive training modalities in cognitive impairment: A systematic review and network meta-analysis.The journal of prevention of Alzheimer's disease · 2025Pooled it
- A world view: Considerations of sociocultural diversity in the study of subjective cognitive decline in Alzheimer's disease and related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.Neurology · 2026Observational
- Sex differentiated and domain specific patterns of longitudinal cognitive decline across subjective cognitive decline and amyloid positivity groups.medRxiv : the preprint server for health sciences · 2026Article
- Minor neuropsychological deficits and stage 2 of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Blood transcriptomic signatures link β-amyloid deposition to molecular pathways across SCD, MCI, and dementia.Frontiers in aging neuroscience · 2026Article
- Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline.JAMA network open · 2025Article
- Assessing outer retinal and choroidal changes in scd: potential for high-risk screening using SS-OCTA.Translational psychiatry · 2025Article
- Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Decreased water exchange rate across the blood-brain barrier throughout the Alzheimer's disease continuum: Evidence from Chinese data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Environmental enrichment is associated with favorable memory-related functional brain activity patterns in older adults.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors.
Funding
Abstract
introductionSubjective cognitive decline (SCD) in amyloid-positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.
methodsEight hundred twenty-one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed-effects models.
resultsIn the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ- participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings. DISCUSSION: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials. HIGHLIGHTS: SCD in amyloid-positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.